192 related articles for article (PubMed ID: 29342281)
1. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
Charpentier C; Malet I; Andre-Garnier E; Storto A; Bocket L; Amiel C; Morand-Joubert L; Tumiotto C; Nguyen T; Maillard A; Rodallec A; Leoz M; Montes B; Schneider V; Plantier JC; Dina J; Pallier C; Mirand A; Roussel C; Signori-Schmuck A; Raymond S; Calvez V; Delaugerre C; Marcelin AG; Descamps D
J Antimicrob Chemother; 2018 Apr; 73(4):1039-1044. PubMed ID: 29342281
[TBL] [Abstract][Full Text] [Related]
2. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Charpentier C; Descamps D
Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
[TBL] [Abstract][Full Text] [Related]
3. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T
J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677
[TBL] [Abstract][Full Text] [Related]
4. E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
Ambrosioni J; Rico JÁF; Nicolás D; Mosquera MM; de Lazzari E; Marcos MÁ; García F; Miró JM;
AIDS; 2019 Aug; 33(10):1613-1617. PubMed ID: 31090546
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
6. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
[TBL] [Abstract][Full Text] [Related]
7. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
8. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Brenner BG; Thomas R; Blanco JL; Ibanescu RI; Oliveira M; Mesplède T; Golubkov O; Roger M; Garcia F; Martinez E; Wainberg MA
J Antimicrob Chemother; 2016 Jul; 71(7):1948-53. PubMed ID: 27029845
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.
Armenia D; Bouba Y; Gagliardini R; Gori C; Bertoli A; Borghi V; Gennari W; Micheli V; Callegaro AP; Gazzola L; Bruzzone B; Giannetti A; Mazzotta V; Vergori A; Mastrorosa I; Colafigli M; Lichtner M; di Biagio A; Maggiolo F; Rizzardini G; d'Arminio Monforte A; Andreoni M; Mussini C; Antinori A; Ceccherini-Silberstein F; Perno CF; Santoro MM;
J Clin Virol; 2020 Sep; 130():104534. PubMed ID: 32769022
[TBL] [Abstract][Full Text] [Related]
10. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
11. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
[TBL] [Abstract][Full Text] [Related]
13. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
15. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
[TBL] [Abstract][Full Text] [Related]
16. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
17. Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon.
Turriziani O; Montagna C; Falasca F; Bucci M; Russo G; Lichtner M; Sobze MS; Vullo V; Pistello M; Antonelli G
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1729-33. PubMed ID: 22214532
[TBL] [Abstract][Full Text] [Related]
18. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
19. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB
AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
